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Tissue Factor Expression in Non-small Cell Lung Cancer:
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Expression, Microvascular Density, and K-ras Mutation
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Pascale Reverdiau, PhD,*†‡ and Yves Gruel, MD*†‡
Introduction: Tissue factor (TF) is the physiological trigger of
blood coagulation, but it could also have an important role in cancer
by regulating VEGF expression and angiogenesis.
Methods: TF expression was studied by real-time PCR in lung
tumors of 64 patients with non-small-cell lung cancer (NSCLC) and
by immunohistochemical analysis. The gene expression of two
VEGF isoforms, VEGF165 and VEGF189, was also evaluated. Mi-
crovascular density (MVD) was studied by measuring Von Wille-
brand Factor (VWF) mRNA levels and by immunohistochemistry
using an anti-CD34 antibody.
Results: TF mRNA levels were significantly lower than in corre-
sponding non-affected lung tissues. However, TF expression was
higher in T3-T4 tumors and this result was confirmed by immuno-
histochemistry. VEGF189 mRNA levels were ten times higher than
those of VEGF165 and well correlated with TF mRNA levels. MVD
was lower in the inner part of tumors than in the adjacent non-
affected lung without being related to TF expression. Finally, codon
12 K-ras mutation was found in 8 lung carcinomas, and higher TF
and VEGF189 mRNA levels were measured in mutated tissues (p 
0.001).
Conclusion: These results suggest that high TF expression in lung
tumors may result from K-ras mutation and contribute to NSCLC
progression, probably via mechanisms other than angiogenesis.
Key Words: Tissue factor, VEGF, Non-small cell lung cancer,
Microvascular density, K-ras mutation.
(J Thorac Oncol. 2008;3: 689–697)
Tissue factor (TF), the physiological trigger of blood co-agulation, is a 47 KDa glycoprotein whose primary se-
quence is similar to that of the type II cytokine receptor.1
Several normal cells such as fibroblasts in the adventitia of
blood vessels constitutively express TF, but cytokines,
growth factors, and endotoxins can also promote TF gene
expression in vascular endothelial cells and circulating mono-
cytes.2 TF has also been recognized as having a key role in
certain cancers, particularly by regulating vascular endothelial
growth factor (VEGF) expression and tumor angiogenesis.3,4 It is
now well established that certain tumor cells such as breast,5
glioma, and pancreatic cancer cells6 express TF at levels
which correlate both with their invasive potential and the
stage of the cancer.7,8
TF expression by tumor cells can enhance angiogenesis
by several mechanisms. On one hand, TF has been shown to
directly regulate VEGF expression in fibroblasts,4 in sarcoma
cells,9 and in melanoma cells,3 and this effect depends on the
intracellular domain of the protein.3 On the other hand,
TF/FVIIa complex triggers local thrombin generation in vivo
and thus may also indirectly induce VEGF signaling through
the protease-activated receptor (PAR)-1 pathway.10,11 In ad-
dition, the TF/FVIIa complex can also activate PAR-2 and
thereby regulate proangiogenic growth factor expression.12
VEGF is a major angiogenic factor that stimulates the
proliferation and migration of endothelial cells. Four iso-
forms with 121, 165, 189, and 206 amino acids, respectively,
can be synthesized by alternative splicing of VEGF mRNA.
The larger isoforms, VEGF189 and VEGF206, are cell-associ-
ated and bind to glycosaminoglycans, whereas the smaller
isoforms (VEGF121 and VEGF165) are secreted in the extra-
cellular matrix.13 On the other hand, VEGF165 can increase
TF expression in endothelial cells.14 Moreover, strong VEGF
expression has been reported to be associated with poor
prognosis in breast carcinoma,15 prostate carcinoma,16 and
melanoma.17,18
Lung cancer is currently the most frequent cause of
cancer-related deaths in the western world, and the major
histologic types of lung tumors (that affect about 80% pa-
tients) are non-small cell lung cancer (NSCLC). In addition,
lung cancer is associated with an increased risk of venous
thromboembolism,19 and by triggering blood coagulation TF
could enhance the development of this complication.
The aim of this study was therefore to investigate
whether TF expression is increased in NSCLC and whether it
correlates with tumor VEGF levels and microvascular density
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(MVD). Finally, we also looked for codon 12 K-rasmutation,
which has been shown to be a prognostic marker in adeno-
carcinoma of the lung20 and was also recently identified as
regulating TF gene expression in colorectal cancer cells.21
PATIENTS, MATERIALS AND METHODS
Patients and Samples
Tissue samples were analyzed from a prospective series
of 64 patients (54 men and 10 women) with NSCLC who had
undergone complete surgical resection of lung tumors as
initial treatment (i.e., without prior radiotherapy or chemo-
therapy) between January 2002 and February 2005. Shortly
after surgery, tissue samples were selected by a pathologist
from the inner part of tumor and from parts of the nonaffected
lung in which no cancer cells could be detected. One-third of
samples was systematically frozen in nitrogen and used for
DNA analysis. Another third was fixed in formalin and
paraffin embedded for conventional histopathological analy-
sis. The last third was conserved at 4°C in a “RNA later”
solution (Ambion, Austin, TX) inhibiting cellular RNases
until further Real time-polymerase chain reaction (RT-PCR)
analysis. In addition, three other cores biopsies were sampled
from the inner part of tumor for tissue microarray (TMA)
analysis. Histologic diagnosis and grade of differentiation
were assigned according to the World Health Organization
criteria for lung tumors,22 and pathologic staging was based
on the revised tumor, node, metastasis Classification of Ma-
lignant tumor.23
Cell Lines
One normal epithelial lung cell line (NL20) and 11
human lung cancer cell lines were also studied: two were
derived from adenocarcinoma (H23, H522), two from squa-
mous cell carcinoma (Calu 1, H520), one from large cell
carcinoma (H460), two from bronchiolo-alveolar carcinoma
(A549, H358) and four from small cell lung cancer (nonad-
herent H69, H209 or adherent DMS53, H69AR). All these
cell lines were obtained from American Type Culture Col-
lection (Manassas, USA) and cultured in appropriate medium
supplemented with endotoxin-free fetal calf serum. In addi-
tion, human umbilical vein endothelial cells (HUVEC) were
freshly collected and cultured as previously described.24
RNA Extraction and cDNA Synthesis
Total RNA was extracted from all tissue samples using
the Perfect RNA Mini Kit (Eppendorf, Hambourg, Germany)
according to the manufacturer’s instructions and as previ-
ously described.25 For cell lines, total RNA was extracted
from 106 cells with the TRIzol reagent (Sigma, Saint Quentin
Fallavier, France). Total RNA yield and purity were deter-
mined by spectrophotometry and only samples with an A260/
A280 ratio above 1.6 were kept for further experiments.
Reverse transcription was performed using 2 g of total RNA in
a final volume of 40L comprising 62.5Mof dNTP, 1.25M
of random decamers (Ambion), AMV-RT buffer 1X concen-
trate, 18U of RNase inhibitor and 15U of AMV-RT (Roche
Diagnostics, Meylan, France) incubated for 1 hour at 42°C.
Real Time PCR Assays for Tissue Factor,
VEGF165, VEGF189, and Von Willebrand
Factor mRNA
RT-PCR assays were developed to evaluate TF, VEGF165,
and VEGF189 mRNA levels in cell lines and tumors. Von
Willebrand Factor (VWF) gene expression was also studied to
evaluate angiogenesis because VWF is a specific marker for
endothelial cells.
The primers used for RT-PCR assays (TF, VEGF165,
and VEGF189) were chosen with the assistance of the primer
3 computer program (Table 1). Previously designed primers
were used to study VWF and 18S ribosomal RNA,26,27 and
18S RNA was therefore used as an internal control to eval-
uate the amount and quality of cDNA in every sample.
All PCR reactions were performed using an iCycler iQ
detection system (Bio-rad, Ivry sur Seine, France) in a total
reaction volume of 25 L containing 2 L of cDNA obtained
from 50 ng of total RNA, 1X Platinum Quantitative PCR
SuperMix-UDG (Invitrogen, Cergy Pontoise, France), 0.2X
Sybr Green solution (Roche) and 0.375, 0.300, 0.25, 0.15 M
of each primer (Proligo, Paris, France) specific for FT,
VEGF165, VEGF189, and VWF, respectively. The optimal
PCR conditions for TF, VEGF165, VEGF189, and VWF were
65°C for 35 cycles, 63°C for 35 cycles, 60°C for 30 cycles,
and 64°C for 30 cycles, respectively. The melting curve was
analyzed for each sample to check PCR specificity. The target
gene expression was quantified in every sample by measuring
the threshold cycle (Ct) value of each reaction and using a
calibration curve specific for every gene studied.
To express our results, standard curves for TF,
VEGF165, VEGF189, and 18S RNA were established using
purified PCR products specific for each gene studied. De-
creasing amounts of these DNA fragments (from 2  107–
2  102 copies) were used as templates and the results
obtained were reproducibly linear. Good correlation coeffi-
cients between the Ct value and the log number of DNA
copies (r2  0.99) were obtained for the four genes studied,
and the efficiency of reactions was between 94 and 99%, with
TABLE 1. Oligonucleotide Primers Used in Real-Time PCR
PCR Product (bp) Forward Primer 533 Reverse Primer 533
TF 114 CCAAACCCGTCAATCAAGT TGCTTCACATCCTTCACAATCTCG
VEGF165 99 AGGCCAGCACATAGGAGAGA CAAGGCCCACAGGGATTTT
VEGF189 106 TGTGAATGCAGACCAAAGAAAGA CGTTTTTGCCCCTTTCCC
VWF 84 AGAAACGCTCCTTCTCGATTATTG TGTCAAAAAATTCCCCAAGATACAC
RNA 18S 120 CGCGGTTCTATTTTGTTGTTTT TTCGCTCTGGTCCGTCTTG
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very low intra and interassay variations (2% and 1%,
respectively). Each sample from both the nonaffected lung
and tumor was studied in duplicate. All results were ex-
pressed as the number of mRNA copies of each gene for 108
copies of 18S RNA.
VWF gene expression was measured to evaluate vas-
cular density in tumors, and standard curves were established
using serial dilutions of total RNA extracted from 106
HUVEC. Results were expressed as “Endothelial Cell Equiv-
alent” per 107 copies of 18S RNA.
Immunoassay for TF
Thirty tumor samples were ground in liquid nitrogen,
homogenized in 1 mL of TNC buffer (50 mM Tris-Hcl, 0.15
mM NaCl, 10 mM CaCl2, 0.02% NaN3, 0.05% Brij35), and
then centrifuged at 10,000g for 15 minutes. The protein
concentration of each supernatant was measured by Lowry’s
method (Total protein Kit, Sigma, Saint Quentin Fallavier,
France). Each sample was then diluted to obtain a protein
concentration of 1 mg/mL. TF protein level was quantified by
Asserachrom TF immunosorbent assay kit (Diagnostica
stago, Asnie`res sur Seine, France), with a range of detection
of 0 to 2000 pg/ml.
Immunohistochemical Analysis for TF and
VEGF Protein Expression and for Tumor
Microvessel Density
Immunohistochemical analysis was performed on for-
malin-fixed and paraffin-embedded samples from the 64 pa-
tients. In 22 cases, both affected and nonaffected lung tissues
(4 m-thick sections) were studied.
In addition, all cancerous samples (n  64) were also
analyzed using a TMA technique and results were compared
with those obtained by molecular analyses. Core biopsies of
1 mm in diameter were taken from each lung cancer tissue
block away from necrotic zones and arrayed in a recipient
paraffin block using a tissue microarrayer (Beecher Instru-
ment, Sun Prairie, Wisconsin), as described.28 Three cores
were displayed in the array for each tumor, resulting in
histologic spots on corresponding slides. Several tissue sam-
ples (from normal lung, normal breast, prostate cancer, and
colon cancer) were tested as controls and presented in the
array as five cores. Slides were incubated for 1 hour with a
murine IgG1 monoclonal anti-TF antibody (specific for amino
acids 1–25 within the extracellular domain; American Diag-
nostica, Stanford) or with a murine monoclonal anti-VEGF
IgG2 antibody specific for the 1 to 140 amino-acid sequence
of human VEGF present in both VEGF165 and VEGF189
isoforms (C-1:sc7269, Santa Cruz Biotechnology, Santa
Cruz). Both antibodies were diluted at 1:100 in antibody diluent
(Dako, Glostrup, Denmark). Biotinylated goat antimouse IgG
were then used as secondary antibodies, and biotin-streptavidin-
peroxidase with diaminobenzidine as chromogen (ChemMate
Detection kit, Dako) was employed for detection. The same
reagents and procedures were used for the conventional
immunohistochemical analyses.
Two independent observers (SR and CB) evaluated the
topography and intensity of the staining, blinded to clinical
and pathologic information.
TF and VEGF staining was graded on a scale from 0 to
3 depending on the intensity of staining and the percentage of
positive tumor cells. Grade 0 represented tumors with malig-
nant cells not or weakly stained. When the intensity was
significant (moderate or strong), lung tumors were defined as
either grade 1 (1–33% of positive cells), or grade 2 (34–66%
of positive cells) or grade 3 (67% of positive cells).29
Finally, tumors were classified as “Low” (grades 0 and 1) or
“High” (grades 2 and 3) for both TF and VEGF.
To evaluate microvessel density, slides were incubated
for 30 minutes in 1:25 diluted monoclonal anti-CD34 anti-
body (IgG1; C QBEmd 10, Dako) and biotinylated goat
antimouse IgG were then used as described above. Individual
microvessels were counted independently at high power mag-
nification (200; area 0.713 mm2) by two observers. Each
score was obtained by adding the vessel counts of 4  200
fields, as previously described.30
Genotyping of Codon 12 K-ras Mutation
in NSCLC
Genomic DNA was extracted from 40 tumor biopsies
using a DNA purification Kit (Qiagen, Courtaboeuf, France).
The K-ras codon12 sequence was amplified by an enriched
PCR-restriction fragment length analysis method as described
by Urban et al.31 When detected in tumors, the presence of
codon12 K-ras mutation was also investigated in nonaffected
lung tissues collected from the same patients.
Statistical Analysis
The sign-test was used to evaluate the distribution of
values in nonaffected lung tissues and tumor samples, and a
Mann-Whitney U test was used to compare the continuous
variables. Spearman’s rank correlation was also used to
analyze the coexpression of the different genes studied in
noncancerous tissues and NSCLC tumors, and a correlation
was considered to be significant when p was 0.05. Multi-
variate analysis was also performed according to principal
component analysis using the SPAD software as previously
described.32 Categorical variables were compared using Fisher’s
exact test, and a p value of 0.05 or less was considered as
statistically significant.
RESULTS
Characteristics of Patients
Sixty-four patients were studied (mean age was 64
years, range: 36–83). The majority of patients were men (54
of 64, 84%) and smokers (57 of 64, 89%). The most frequent
histologic type was adenocarcinoma (37 of 64; 57.8%), fol-
lowed by squamous cell carcinoma (19 of 64; 29.5%), and
eight tumors (12.7%) were classified as other histologic
subtypes, corresponding to large cell carcinoma or mixed
type. Tumors were more frequently of small size (T1–T2: 52
of 64; 81%) and without lymph node involvement (39 of 64;
61%) (Table 2).
TF Gene Expression in NSCLC Tumors and in
Pulmonary Cell Lines
Specific TF mRNA levels were significantly lower in
NSCLC tumors (median: 11,540 per 108 copies 18S RNA)
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than in corresponding nonaffected lung tissues (34,350 cop-
ies; p  0.0085) (Figure 1).
TF gene expression was also compared with clinico-
pathological features using a descriptive multivariate analysis
and was significantly higher in T3–T4 tumors than in T1–T2
tumors (p  0.04) and in samples collected from patients
with stages III–IV (p  0.03). No other significant differ-
ences were found according to sex, histologic type, and
differentiation or lymph node status (Table 2).
TF gene expression was also evaluated in 12 pulmonary
cell lines, 11 derived from lung tumors (7 NSCLC and 4
small cell lung cancers) and 1 from normal lung tissue
(NL20) (Figure 1). TF gene expression was variable from one
cell line to another (3–57,250 copies/108 copies of 18S RNA)
and almost undetectable in the two SCLC cell lines that were
nonadherent (H69 and H209).
TF Protein Expression in NSCLC Tumors
TF antigen levels measured in 30 NSCLC tumors with
a specific immunoassay (range  22–164 pg/mg of total
protein) were significantly correlated with mRNA levels
(Spearman correlation, r  0.84; p  0.0001) (data not
shown).
Immunohistochemical study was performed on nonaf-
fected lung samples and tumors collected from 22 patients to
identify the cells expressing TF. Normal bronchial epithelial
cells were positive for TF in all nonaffected lung biopsies,
particularly in the basal pole. On the other hand, TF was
detected in a few alveolar macrophages and in some capillary
endothelial cells. The TF staining was variable from one
cancerous biopsy to another and TMA was then performed on
all 64 tumors. In the majority of tumors (n 47, 73.5%), less
than one-third of cells were positive for TF staining (grade
1) and these samples were classified in the “Low TF”
group. Only 17 NSCLC tumors (26.5%) exhibited strong TF
protein expression (staining score  grade 2 or 3) and they
were therefore categorized in the “High TF” group (Figure 2).
As expected, median TF mRNA levels were higher in “High
TF” tumors than in “Low TF” samples (66,440 versus 9315
copies/108 18S; p  0.0001).
TF protein expression evaluated by immunohistochem-
istry was also compared with the clinicopathological features.
A significant correlation was found between high TF expres-
sion and tumor status (T3–T4) (p  0.01; Fisher’s exact test)
but none with the stage or other features of NSCLC (i.e., sex,
TABLE 2. Relationship Between TF Gene Expression (Number of Copies per 108 Copies of 18S RNA) and
Immunohistochemical Groups (Low and High Expression) and Clinicopathological Features (Fisher’s Exact Test)
Features n
Median TF mRNA Levels
(Range) p
High TF
Expression n (%)
Low TF
Expression n (%) p
All 64 11540 (60–309,600) 17 (26.5) 47 (73.5)
Age (yrs) 65 (36–83) 11540 (60–309,600) 65 (44–78) 66 (36–83)
Sex
Male 54 10100 (60–309,600) 0.33 15 (28) 39 (72) 0.98
Female 10 11540 (60–309,600) 0.33 2 (20) 8 (80)
Tobacco
Yes 57 101,000 (60–309,600) 0.01 14 (83) 43 (91) 0.37
No 7 15,790 (720–85,180) 0.01 3 (43) 4 (57)
Histology
AC 37 9320 (60–309,600) 0.27 9 (24) 28 (76) 0.78
SCC 19 11,590 (720–154,800) 0.39 5 (26) 14 (74)
Other 8 13,130 (1680–256,000) 0.079 3 (37.5) 5 (62.5)
Differentiation
Yes 46 8600 (60–154,800) 0.08 11 (24) 34 (76) 0.91
No 18 11,280 (100–309,600) 0.08 5 (28) 13 (72)
Tumor status
T1 and T2 52 8530 (100–154,800) 0.04 10 (19) 42 (81) 0.01
T3 and T4 12 19,150 (60–309,600) 0.04 7 (58) 5 (42)
Node status
N0 39 10,500 (100–309,600) 0.4 10 (26) 28 (74) 0.95
N1–N2 25 7150 (60–154,800) 0.4 7 (28) 19 (72)
Metastasis
M0 53 11,590 (60–309,600) 0.06 15 (28) 38 (72) 0.49
M1 11 5520 (110–137,430) 0.06 2 (18) 9 (82)
Stage
I–II 34 9780 (100–272,400) 0.03 8 (23) 26 (77) 0.58
III–IV 30 17710 (60–309,600) 0.03 9 (30) 21 (70)
AC, adenocarcinoma; SCC, squamous cell carcinoma.
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histologic type, and differentiation or lymph node status)
(Table 2).
VEGF Expression and Microvascular Density in
NSCLC Tumors
VEGF165 and VEGF189 gene expression was evaluated
in NSCLC tumors and paired nonaffected lungs by specific
RT-PCR and was variable from one patient to another.
VEGF165 gene expression was not significantly different in
either tissue type (p  0.158) (Figure 1). In contrast,
VEGF189 mRNA levels were lower in tumors than in corre-
sponding nonaffected lungs (p  0.0001) (Figure 1).
On the other hand, VEGF165 gene expression was 5- to
10-fold lower than those of VEGF189, but the numbers of
transcripts of these two genes were strongly correlated in both
categories of lung tissue (p  0.0001; Table 3). In contrast,
VEGF165 mRNA levels were not correlated with those of TF.
A weak correlation was only found between the expression of
TF and VEGF189 genes in both nonaffected lungs and
NSCLC tumors (Table 3).
VEGF165 and VEGF189 transcripts were also measured
in 12 pulmonary cell lines (Figure 1) and no correlation with
TF gene expression was evidenced.
VEGF protein expression was also evaluated by con-
ventional immunohistochemical analysis (n  22) and with
TMAs (n  64) in the lung tumors using a monoclonal
antibody that recognized both VEGF165 and VEGF189 iso-
forms. Significant staining was specifically visualized in
bronchial epithelial cells (apical pole), in a few alveolar
macrophages and in stroma cells (fibroblasts). Twenty-six
samples (40.6%) were classified in the “High VEGF” group
according to the percentage of positive cells and 38 (60.4%)
in the “Low VEGF” group, but this was not related to TF
protein expression (p  0.26).
Tumor MVD was evaluated by measuring VWF gene
expression in lung biopsies of the 64 patients using a specific
FIGURE 1. TF, VEGF189 and VEGF165
gene expression in noncancerous lung
tissues (NA, empty circles), nonsmall
cell lung tumors (T, filled circles) and
pulmonary cell lines (CL) from a nor-
mal lung (NL20,1), NSCLC (f, all
adherent) and SCLC (adherent Œ and
nonadherent ‚). Median values are
presented as plain bars. Each point is
representative of two (tissues) or three
(cell lines) separate experiments.
FIGURE 2. Immunohistochemical staining for TF in lung
tumors. Cancerous cells positive for TF (3) were only seen
in samples with high TF expression.
TABLE 3. Spearman Correlation Matrix to Evaluate TF,
VEGF, and VWF Gene Coexpression in Nonaffected Lungs
and NSCLC Tumors (p Values in Brackets)
TF VEGF189 VEGF165
Nonaffected
lungs
TF 1
VEGF189 r  0.29 (0.01) 1
VEGF165 r  0.038 (0.39) r  0.43 (0.0001) 1
VWF r  0.32 (0.005) r  0.316 (0.006) r  0.002 (0.49)
NSCLC
tumors
TF 1
VEGF189 r  0.23 (0.03) 1
VEGF165 r  0.035 (0.42) r  0.64 (0.0001) 1
VWF r  0.05 (0.34) r  0.20 (0.06) r  0.32 (0.005)
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RT-PCR method. Results were expressed in equivalent en-
dothelial cells for 107 copies of 18S RNA using standard
curves established by measuring VWF mRNA levels in
HUVEC. VWF gene expression was significantly lower in
NSCLC tumors (p  0.0001), reflecting a striking reduction
in the number of endothelial cells in cancerous tissues com-
pared with nonaffected lungs (Figure 3A).
Moreover, VWF and TF mRNA levels were only cor-
related in noncancerous lung tissues (p  0.005), but not in
NSCLC tumors (p  0.34) (Table 3).
MVD was also studied by TMA in all tumors and by
conventional immunohistochemistry in both nonaffected and
cancerous lungs of 22 patients.
The CD34 staining score evaluated using TMA was
well correlated with the number of endothelial cells estimated
by measuring VWF gene expression (r  0.67; p  0.001).
On the other hand, it was significantly lower in NSCLC
tumors (median score  287, range: 65–585) than in paired
nonaffected lungs (450, 75–735; p  0.0001) and this result
also demonstrated that MVD was considerably reduced in
cancerous tissues. The most frequent picture visualized in
conventional immunohistochemistry was in fact character-
ized by the presence of cancer cells that filled alveoli and
pushed away pre-existing vessels (Figure 3B). In addition,
MVD was not significantly different in “Low TF” and “High
TF” tumors (median  264 versus 245, p  0.85).
Finally, there was no relationship between tumor
VEGF expression or MVD and the clinicopathological fea-
tures of NSCLC according to the multivariate analysis
performed.
Codon 12 K-ras Mutation and Relationship
with TF, VEGF189, VEGF165, and
VWF Expression
The presence of codon 12 K-ras gene mutation was
investigated in genomic DNA extracted from 40 tumors using
an enriched PCR-restriction fragment length analysis. This
mutation was found in eight tumors (20%), which were all
adenocarcinomas, and in none of the nonaffected lung sam-
ples. Importantly, TF and VEGF189 mRNA levels were
higher in K-ras mutated tumors (p  0.0001), but not those
of VEGF165 and VWF (Table 4). Moreover, a significant
correlation between TF and VEGF189 gene expression was
found in mutated tissues (Spearman rank correlation test; r 
0.68, p  0.03) but not in lung tumors without K-ras
mutation (r  0.27).
On the other hand, the codon 12 K-ras gene mutation
was present in 4 of 11 pulmonary cancer cell lines (A549,
H358, Calu1, and H23). TF and VEGF189 gene expression
FIGURE 3. Microvascular density (MVD) evaluated by RT-
PCR specific for VWF gene (A) and immunohistochemical
staining of endothelial cells (B). (1) Results of RT-PCR ex-
pressed as ECE (Endothelial Cell Equivalent) per 107 copies
of 18S RNA (control gene) in nonaffected lungs (NA) and
tumors (T) of 64 patients. (2) CD34 staining of lung tissues
from one patient with adenocarcinoma. Endothelial cells and
vessels (3) were less numerous and less frequently visualized
in the tumor (T) than in nonaffected lung tissue (NA).
TABLE 4. Median TF, VEGF165, VEGF189, and VWF mRNA Levels in NSCLC Tumors and in Cancerous
Pulmonary Cell Lines According to Codon 12 K-ras Status i.e., Wild Type (WT) and Mutated (Ranges
in Brackets)
n TF VEGF165 VEGF189 VWF
NSCLC
Wild type K-ras 32 11,045 (50–309,550) 2880 (445–13,187) 5935 (50–37,1480) 6548 (239–40,123)
Mutated K-ras 8 48480a (760–154,830) 1250 (16–12,594) 9150a (1166–286,430) 5048 (560–21,985)
Pulmonary cell lines
Wild type K-ras 7 1122 (4–20,866) 1702 (126–11,960) 131 (5–4873) NA
Mutated K-ras 4 6549 (224–57,250) 6062 (2–21,460) 916 (15–14,776) NA
a p  0.0001.
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also seemed higher in mutated cells (Table 4) but no statis-
tical analysis was performed because of the low number of
cell lines studied.
DISCUSSION
In this study, the expression of TF and VEGF189 genes
was found to be significantly decreased in NSCLC tumors
compared with nonaffected lungs and MVD was considerably
reduced. TF mRNA levels were assayed by a specific and
sensitive molecular method and the results obtained corre-
lated well with TF protein levels measured by enzyme-linked
immunosorbent assay. On the other hand, TF expression was
variable from one tumor to another, and such variation was
also found with cancerous pulmonary cell lines. This vari-
ability in TF expression has already been reported in two
studies, which had also demonstrated that TF was more
expressed in pulmonary cell lines derived from metastases
and in cancerous tissues from patients with advanced lung
cancer.8,33 Our results were in agreement with these findings,
because TF mRNA levels were higher in tumors from pa-
tients with the most severe stages of NSCLC, i.e., those with
T3–T4 tumor status (p  0.04) and stages III–IV (p  0.03).
In addition, strong TF protein staining was more frequently
observed in cancerous cells in patients with T3–T4 tumor
status (p  0.01).
Previous studies in patients with colorectal and breast
cancer have shown that TF expression in tumors is correlated
with clinical progression.34,35 In addition, it was also recently
demonstrated that TF-VIIa signaling was a major contributor
to tumor growth in breast cancer.36
TF expression was first studied in human NSCLC by
immunohistochemistry by Koomagi and Volm who also
found that only some tumors synthesized TF (65 of 191;
32%).37 Kaplan-Meier survival analysis also revealed that
survival times were longer in patients with TF-negative
tumors than in patients with TF-positive tumors. In addition,
a relationship between TF and metastasis has been demon-
strated in patients with NSCLC.8 Altogether these results and
our data support that tumor TF could be a prognostic factor in
lung cancer.
Mechanisms that regulated TF expression in cancer
cells remained unknown. TF synthesis may be particularly
controlled by several tumor-related events, including activa-
tion of oncogenes, inactivation of tumor suppressor genes and
changes in the tumor microenvironment such as hypoxia or
inflammation.38
A link between TF expression and K-ras has recently
been reported in colorectal cancer cells,21 and we therefore
looked for the presence of a single mutation in codon-12 of
this oncogene which has been shown to be relatively frequent
in lung cancer.39 This point mutation was present in 20% of
the tumors studied, which were all adenocarcinomas, and was
absent in noncancerous lung tissues sampled in the same
patients. Interestingly, both TF and VEGF189 mRNA levels
were higher in NSCLC tumors exhibiting the K-ras mutation.
In addition, a significant correlation between the levels of TF
and VEGF189 transcripts could be evidenced only in mutated
tissues. A common axis of regulation may therefore exists
between TF and VEGF189 involving the K-ras pathway in
NSCLC. However, other oncogenes such as EGFR and tumor
suppressor genes such as P53 and PTEN may also regulate
TF gene expression in NSCLC, as in other types of cancer.38
TF has been identified as an important regulator of
angiogenesis and mainly acts through up-regulation of
VEGF.40 According to our findings, VEGF189 is the major
VEGF isoform synthesized in NSCLC tumors, with five
times higher mRNA levels measured compared with
VEGF165. However, the expression of VEGF165 andVEGF189
genes was highly correlated in lung tissues. These findings
showing an over expression of VEGF189 in lung tumors are in
agreement with those of a previous study which also demon-
strated the impact of this vascular growth factor on the
prognosis of NSCLC.41 VEGF isoforms probably have dif-
ferent functions in cancer tissues. VEGF165 is mainly secreted
and freely diffusible whereas VEGF189, which is more basic
and binds to heparin, is cell-associated and almost completely
sequestered in the extracellular matrix.13 Both VEGF165 and
VEGF189 are proangiogenic but only VEGF189 has been
identified to be directly involved in tumor growth and this
effect could involve non angiogenic processes such as cell
adhesion.42,43 In our study, although VEGF189 mRNA levels
were correlated with those of TF in lung tumors, but only
when K-ras was mutated and no relationship was found
between TF and VEGF protein levels evaluated by immuno-
histochemistry. This apparent discrepancy could in part be
because of the use of an antibody that binds both to VEGF165
and VEGF189 isoforms. On the other hand, no apparent
relationship could be found between the expression of TF and
VEGF165 genes in lung tissues, whether cancerous or not.
Such a relationship has previously been demonstrated in
melanoma,3 but such tumors are highly vascularized. In
contrast, NSCLC tumors contain fewer vessels than noncan-
cerous lungs, as shown by our evaluation of MVD.
MVD was evaluated in lung tumors by two different
methods, one based on the use of a CD34-specific antibody
that is very sensitive for staining endothelial cells in human
lungs30 and the other being a PCR method measuring tissue
VWF mRNA levels developed to estimate lung MVD more
precisely. VWF is a highly specific marker for vascular
endothelial cells and many authors have studied the localiza-
tion of the VWF antigen by immunohistochemistry to eval-
uate MVD in cancerous tissues.44 VWF mRNA levels were
10-times lower in tumors compared with noncancerous lung
tissues, correlated well with CD34-specific staining scores,
and demonstrated that MVD is reduced in NSCLC tumors.
These results are in agreement with those of Eberhard et al.,
who also found that MVD counts were higher in normal lungs
(348%) than in carcinomas and that new proliferating endo-
thelial cells were rare in tumors.45 This low MVD also
explains why TF expression is lower in tumors than in
nonaffected tissues. The noncancerous lung is indeed highly
vascularized and TF gene is likely over-expressed in many
patients at risk for cancer such as heavy smokers.46
The impact on the clinical prognosis of tumor MVD
and angiogenesis in NSCLC has been documented by several
studies.47 However, we did not find any correlation between
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VWF gene expression in tumors and NSCLC stage. In fact,
tumor MVDmight not necessarily be such a good indicator of
angiogenesis in most NSCLC as in other human cancers.48
Several studies have shown clearly that at least half NSCLC
grow by exploiting pre-existing vessels and without morpho-
logic evidence of neo-angiogenesis.49–51 On the other hand,
MVD has previously been shown to decrease from the in-
vading front to the inner part of NSCLC tumors.52 This
feature might also have contributed to our results since the
biopsies analyzed were taken only from the inner parts of
lung tumors, in which the cancerous cells filled the alveoli in
most cases and therefore the only vessels present were those
trapped in the alveolar septa.
In conclusion, this study demonstrates that TF gene
expression and MVD are reduced in NSCLC tumors com-
pared with nonaffected lung tissue. However, the TF gene is
more highly expressed in tumors when the K-ras oncogene is
mutated and in advanced stages of NSCLC. Taken together,
our results support the hypothesis that an axis involving
TF/VEGF189 and the K-ras pathway has a role in the pro-
gression of lung carcinoma.
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